A phase 1, open-label, dose-escalation study of SGN-CD19B in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma - Regional Cancer Care Associates LLC

Clinical Trials

A phase 1, open-label, dose-escalation study of SGN-CD19B in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

Type of Cancer
Lymphoma
Locations
Hackensack
Sponsor
Seattle Genetics
Protocol Number
SGN19B-001
Cancer Diagnosis
To Learn More Call
201-510-0910